STAB - Statera Biopharma plunges 19% on pricing $2.0M stock offering

Statera Biopharma (NASDAQ:STAB) slumps 19.1% premarket Monday after the firm enters into a securities purchase agreement with a certain institutional investor to purchase ~$2.0M worth of its common stock and warrants in a registered direct offering. Under the terms, the Company has agreed to sell ~2.0M shares of its common stock and warrants to purchase ~2.0M shares of common stock. The warrants will be exercisable immediately, have an exercise price of $1.00/share, and will expire five years from the initial exercise date. Offering is expected to close on or about February 9, 2022.

For further details see:

Statera Biopharma plunges 19% on pricing $2.0M stock offering